Patiromer
As of the edition of 20 October 2026, Patiromer is a small molecule: marketed, first approved in 2017 (EU).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Veltassa
- First approved
- 19 July 2017 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Vifor Fresenius Medical Care Renal Pharma
- Registered trials
- 19, 4 stopped early
- Disease areas
- Nutrition and metabolism; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 2 | 8 | 5 | 1 | 2 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 7 | 5 | 0 | 2 |
| All trials | 19 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Vifor Fresenius Medical Care Renal Pharma | Applicant and Lead sponsor of trials | 2017 to now |